LBS alumnus Will West leads $220m funding round for cancer treatment trials
CellCentric, led by LBS alumnus Will West, has secured an oversubscribed $220m financing to advance pivotal trials
London Business School alumnus Will West (MBA 2001), CEO and founder of CellCentric, has announced a $220m oversubscribed Series D financing to advance pivotal trials of the company’s multiple myeloma treatment, inobrodib.
CellCentric, the Cambridge-based biotechnology company, said the financing will support late-stage clinical trials of its cancer treatment inobrodib.
The funding round was led by Venrock Healthcare Capital Partners, with participation from Fidelity Investments, Sofinnova Partners, HBM Healthcare, and existing investors including Pfizer and RA Capital Management.
The proceeds will fund the registration-enabling Phase 2 and Phase 3 DOMMINO trials in the UK, US and globally, as well as further development of inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma.
West said the investment reflected confidence in the treatment’s potential to address a major unmet need for patients following bispecific T cell engager and anti-BCMA therapies.
Clinical data presented in 2025 showed promising response rates in heavily pretreated patients, with CellCentric positioning inobrodib as a potentially transformative all-oral treatment option for multiple myeloma.